Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men

被引:37
|
作者
Dumond, Julie B. [1 ]
Reddy, Y. Sunila [1 ]
Troiani, Luigi [1 ]
Rodriguez, Jose E. [2 ,3 ]
Bridges, Arlene S. [1 ]
Fiscus, Susan A. [1 ]
Yuen, Geoffrey J. [4 ]
Cohen, Myron S. [1 ]
Kashuba, Angela D. M. [1 ]
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Univ Puerto Rico, Sch Med, Dept Biochem, San Juan, PR 00936 USA
[3] Puerto Rico Inst Forens Sci, San Juan, PR USA
[4] GlaxoSmithKline, Res Triangle Pk, NC USA
关键词
HIV; pharmacokinetics; nucleoside triphosphate; antiretroviral therapy; genital tract;
D O I
10.1097/QAI.0b013e31816de21e
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To quantitate extracellular and intracellular zidovudine (ZDV) and lamivudine (3TC) concentrations in blood and semen of HIV-1-infected men. Design: Nonblind, single-center, open-label pharmacokinetic (PK) study in 14 subjects receiving ZDV plus 3TC. Methods: Paired blood and semen samples were obtained during I intensive visit and 3 single time point visits over 2 weeks. Extracellular ZDV and 3TC concentrations were measured in blood plasma (BP) and seminal plasma (SP), and intracellular ZDV and 3TC triphosphate (TP) concentrations were measured in isolated mononuclear cells using validated methods. HIV-1 RNA was measured in blood and semen. PK parameters were estimated using non-compartmental analysis. Results: Median (interquartile range [IQR]) SP/BP area under the time-concentration curve over the 12-hour dosing interval (AUC(0-12h)) ratios for ZDV and 3TC were 2.28 (1.48 to 2.97) and 6.67 (4.10 to 9.14), respectively, whereas individual SP/BP concentration ratios ranged from 1.9 to 91.4. Intracellular median (IQR) SP/BPAUC(0-12h) ratios for ZDV-TP and 3TC-TP were 0.36 (0.30 to 0.37) and 1.0 (0.62 to 1.30), respectively, whereas individual SP/BP concentration ratios ranged from 0.11 to 2.9. HIV-1 RNA was undetectable in both compartments. Conclusions: ZDV and 3TC SP exposures are 2- to 6-fold greater than BP exposures. Seminal ZDV-TP exposures are similar to 40% of those found in peripheral blood mononuclear cells (PBMCs), whereas 3TC-TP exposures are similar to PBMC exposures. PK variability makes individual SP/BP ratios a suboptimal surrogate for genital tract exposure.
引用
收藏
页码:156 / 162
页数:7
相关论文
共 50 条
  • [31] LONG-TERM ZIDOVUDINE TREATMENT OF ASYMPTOMATIC HIV-1-INFECTED SUBJECTS
    MULDER, JW
    DEWOLF, F
    GOUDSMIT, J
    CLOAD, PA
    COUTINHO, RA
    FIDDIAN, AP
    SCHELLEKENS, PT
    VANDERNOORDAA, J
    LANGE, JMA
    [J]. ANTIVIRAL RESEARCH, 1990, 13 (03) : 127 - 138
  • [32] INVIVO COMPARISON OF ZIDOVUDINE RESISTANCE IN BLOOD AND CSF OF HIV-1-INFECTED PATIENTS
    WILDEMANN, B
    HAAS, J
    EHRHART, K
    HAHN, M
    WAGNER, H
    STORCHHAGENLOCHER, B
    [J]. NEUROLOGY, 1993, 43 (04) : A266 - A266
  • [33] Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients
    Rolinski, B
    Bogner, JR
    Sadri, I
    Wintergerst, U
    Goebel, FD
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 15 (03): : 192 - 197
  • [34] Population Pharmacokinetics Study of Recommended Zidovudine Doses in HIV-1-Infected Children
    Fauchet, Floris
    Treluyer, Jean-Marc
    Frange, Pierre
    Urien, Saik
    Foissac, Frantz
    Bouazza, Naim
    Benaboud, Sihem
    Blanche, Stephane
    Hirt, Deborah
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (10) : 4801 - 4808
  • [35] Effect of prenatal zidovudine on disease progression in perinatally HIV-1-infected infants
    de Souza, RS
    Gómez-Marín, O
    Scott, GB
    Guasti, S
    O'Sullivan, MJ
    Oliveira, RH
    Mitchell, CD
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 24 (02) : 154 - 161
  • [36] NEUTROPENIA IN AN HIV-1-INFECTED RENAL-TRANSPLANT RECIPIENT TREATED WITH ZIDOVUDINE
    ERICE, A
    RHAME, FS
    DUNN, DL
    CHINNOCK, B
    BALFOUR, HH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 259 (23): : 3407 - 3408
  • [37] Zidovudine genotypic resistance in HIV-1-infected newborns in the French Perinatal Cohort
    Masquelier, B
    Chaix, ML
    Burgard, M
    Lechenadec, J
    Doussin, A
    Simon, F
    Cottalorda, J
    Izopet, J
    Tamalet, C
    Douard, D
    Fleury, H
    Mayaux, MJ
    Blanche, S
    Rouzioux, C
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2001, 27 (02) : 99 - 104
  • [38] Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women
    Melvin, AJ
    Burchett, SK
    Watts, DH
    Hitti, J
    Hughes, JP
    McLellan, CL
    King, PD
    Johnson, EJ
    Williams, BL
    Frenkel, LM
    Coombs, RW
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 14 (03): : 232 - 236
  • [39] Plasma levels of zidovudine twice daily compared with three times daily in six HIV-1-infected children
    Bergshoeff, AS
    Fraaij, PLA
    Verweij, C
    van Rossum, AMC
    Verweel, G
    Hartwig, NG
    de Groot, R
    Burger, DM
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (06) : 1152 - 1154
  • [40] Semen Extracellular Vesicles From HIV-1-Infected Individuals Inhibit HIV-1 Replication In Vitro, and Extracellular Vesicles Carry Antiretroviral Drugs In Vivo
    Welch, Jennifer L.
    Kaddour, Hussein
    Winchester, Lee
    Fletcher, Courtney V.
    Stapleton, Jack T.
    Okeoma, Chioma M.
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2020, 83 (01) : 90 - 98